Concise Review: Exciting Cells: Modeling Genetic Epilepsies with Patient-Derived Induced Pluripotent Stem Cells

Stem Cells

Volumn 34, Issue 1, 2016, Pages 27-33

  Tidball, Andrew M ^a   Parent, Jack M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Channelopathies; Drug discovery; Epilepsy; Human induced pluripotent stem cells; Patient specific modeling

Indexed keywords

ASTROCYTE; CHANNELOPATHY; DISEASE MODEL; EPILEPSY; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; REVIEW; ANIMAL; CYTOLOGY; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; PATHOLOGY;

ION CHANNEL;

ANIMALS; CHANNELOPATHIES; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; ION CHANNELS; PHENOTYPE;

EID: 84954387235     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2203     Document Type: Review

References (55)

1. Takahashi K, Tanabe K, Ohnuki M, et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
2. Marchetto MC, Winner B, Gage FH,. Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum Mol Genet 2010; 19: R71-R76.
3. Okita K, Yamakawa T, Matsumura Y, et al., An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 2013; 31: 458-466.
4. Nishimura K, Sano M, Ohtaka M, et al., Development of defective and persistent Sendai virus vector a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 2011; 286: 4760-4771.
5. Okita K, Matsumura Y, Sato Y, et al., A more efficient method to generate integration-free human iPS cells. Nat Methods 2011; 8: 409-412.
6. Marion RM, Strati K, Li H, et al., Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 2009; 4: 141-154.
7. Srikanth P, Young-Pearse TL,. Stem cells on the brain: Modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells. J Neurogenet 2014; 28: 5-29.
8. Ran FA, Hsu PD, Lin C-Y, et al., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013; 154: 1380-1389.
9. Schwank G, Koo B-K, Sasselli V, et al., Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013; 13: 653-658.
10. Miyaoka Y, Chan AH, Judge LM, et al., Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat Methods 2014; 11: 291-293.
11. Hirtz D, Thurman D, Gwinn-Hardy K, et al., How common are the "common" neurologic disorders? Neurology 2007; 68: 326-337.
12. Olafsson E, Ludvigsson P, Hesdorffer D, et al., Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: A prospective study. Lancet Neurol 2005; 4: 627-634.
13. Thurman DJ, Hesdorffer DC, French JA,. Sudden unexpected death in epilepsy: Assessing the public health burden. Epilepsia 2014; 55: 1479-1485.
14. Shoffner JM, Lott MT, Lezza AM, et al., Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA Lys mutation. Cell 1990; 61: 931-937.
15. Noebels J,. Pathway-driven discovery of epilepsy genes. Nat Neurosci 2015; 18: 344-350.
16. Chiron C, Dulac O,. The pharmacologic treatment of Dravet syndrome. Epilepsia 2011; 52: 72-75.
17. Carvill GL, Heavin SB, Yendle SC, et al., Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 2013; 45: 825-830.
18. O'Brien JE, Meisler MH,. Sodium channel SCN8A (Nav1. 6): Properties and de novo mutations in epileptic encephalopathy and intellectual disability. Front Genet 2013; 4.
19. Phenome E, Consortium EK,. De novo mutations in epileptic encephalopathies. Nature 2013; 501: 217-221.
20. Fujiwara T, Sugawara T, Mazaki-Miyazaki E, et al., Mutations of sodium channel α subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003; 126: 531-546.
21. Meng H, Xu HQ, Yu L, et al., The SCN1A mutation database: Updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat 2015; 36: 573-580.
22. Zeng H, Shen EH, Hohmann JG, et al., Large-scale cellular-resolution gene profiling in human neocortex reveals species-specific molecular signatures. Cell 2012; 149: 483-496.
23. Dolce A, Ben-Zeev B, Naidu S, et al., Rett syndrome and epilepsy: An update for child neurologists. Pediatr Neurol 2013; 48: 337-345.
24. Marchetto MC, Carromeu C, Acab A, et al., A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010; 143: 527-539.
25. Cheung AY, Horvath LM, Grafodatskaya D, et al., Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet 2011; 20: 2103-2115.
26. Maezawa I, Swanberg S, Harvey D, et al., Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci 2009; 29: 5051-5061.
27. Ricciardi S, Ungaro F, Hambrock M, et al., CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol 2012; 14: 911-923.
28. Livide G, Patriarchi T, Amenduni M, et al., GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells. Eur J Hum Genet 2015; 23: 195-201.
29. Dhar S, Del Gaudio D, German J, et al., 22q13. 3 deletion syndrome: Clinical and molecular analysis using array CGH. Am J Med Genet Part A 2010; 152: 573-581.
30. Shcheglovitov A, Shcheglovitova O, Yazawa M, et al., SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 2013; 503: 267-271.
31. Berry-Kravis E, Potanos K,. Psychopharmacology in fragile X syndrome-Present and future. Ment Retard Dev Disabil Res Rev 2004; 10: 42-48.
32. Liu J, Kos̈cielska KA, Cao Z, et al., Signaling defects in iPSC-derived fragile X premutation neurons. Hum Mol Genet 2012: dds207.
33. Halevy T, Czech C, Benvenisty N,. Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Rep 2015; 4: 37-46.
34. Yazawa M, Hsueh B, Jia X, et al., Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471: 230-234.
35. Paşca SP, Portmann T, Voineagu I, et al., Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011; 17: 1657-1662.
36. Higurashi N, Uchida T, Lossin C, et al., A human Dravet syndrome model from patient induced pluripotent stem cells. Mol Brain 2013; 6: 19.
37. Jiao J, Yang Y, Shi Y, et al., Modeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons. Hum Mol Genet 2013; 22: 4241-4252.
38. Liu Y, Lopez-Santiago LF, Yuan Y, et al., Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol 2013; 74: 128-139.
39. Itzhaki I, Maizels L, Huber I, et al., Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471: 225-229.
40. Davis RP, Casini S, van den Berg CW, et al., Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012; 125: 3079-3091.
41. Moretti A, Bellin M, Welling A, et al., Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363: 1397-1409.
42. Hu B-Y, Weick JP, Yu J, et al., Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA 2010; 107: 4335-4340.
43. Kim K, Doi A, Wen B, et al., Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467: 285-290.
44. Müller F-J, Schuldt BM, Williams R, et al., A bioinformatic assay for pluripotency in human cells. Nat Methods 2011; 8: 315-317.
45. Sandoe J, Eggan K,. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci 2013; 16: 780-789.
46. Nicholas CR, Chen J, Tang Y, et al., Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 2013; 12: 573-586.
47. Tang X, Zhou L, Wagner AM, et al., Astroglial cells regulate the developmental timeline of human neurons differentiated from induced pluripotent stem cells. Stem Cell Res 2013; 11: 743-757.
48. Sukigara S, Dai H, Nabatame S, et al., Expression of astrocyte-related receptors in cortical dysplasia with intractable epilepsy. J Neuropathol Exp Neurol 2014; 73: 798-806.
49. Moore AR, Filipovic R, Mo Z, et al., Electrical excitability of early neurons in the human cerebral cortex during the second trimester of gestation. Cereb Cortex 2009; 19: 1795-1805.
50. Bardy C, van den Hurk M, Eames T, et al., Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro. Proc Natl Acad Sci 2015: 201504393.
51. Wainger BJ, Kiskinis E, Mellin C, et al., Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep 2014; 7: 1-11.
52. McConnell ER, McClain MA, Ross J, et al., Evaluation of multi-well microelectrode arrays for neurotoxicity screening using a chemical training set. Neurotoxicology 2012; 33: 1048-1057.
53. Lancaster MA, Renner M, Martin C-A, et al., Cerebral organoids model human brain development and microcephaly. Nature 2013; 501: 373-379.
54. Espuny-Camacho I, Michelsen KA, Gall D, et al., Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo. Neuron 2013; 77: 440-456.
55. Cunningham M, Cho J-H, Leung A, et al., hPSC-derived maturing GABAergic interneurons ameliorate seizures and abnormal behavior in epileptic mice. Cell Stem Cell 2014; 15: 559-573.